SEC Filing Analysis: NEOGEN CORP (NEOG)

Executive Summary

• Trading Significance: Low
• Key Takeaway: A director received a routine equity award as part of their compensation, consisting of both common stock and options, with a negligible impact on the company's capital structure.
• Market Impact: Neutral. This type of transaction is standard for director compensation and is not expected to influence the stock price.

Company Information

Field	Value
Company	NEOGEN CORP
Ticker Symbol	NEOG
CIK	0000711377
Industry	In Vitro & In Vivo Diagnostic Substances

Insider Information

Field	Value
Name	Woteki Catherine E
CIK	0001829079
Title/Position	null
Relationship	Director

Transaction Details

Field	Value
Form Type	4
Transaction Date	2025-10-23
Transaction Code	A (Grant)
Security Type	Common Stock
Shares Involved	19,769
Price Per Share	$6.07
Total Value	$120,000.83
Shares Owned After	35,084
Ownership Type	Direct

Financial Impact Assessment

Transaction Materiality

Metric	Value
Transaction Value	$120,000.83
% of Market Cap	0.009%
Shares Transacted	19,769
% of Shares Outstanding	0.009%
Post-Transaction Ownership	35,084 shares (0.016% of outstanding)
Materiality Assessment	Low

Impact Evaluation

• Market Cap Context: The transaction value of ~$120k is insignificant relative to NEOGEN's $1.35 billion market capitalization.
• Ownership Concentration: The director's post-transaction ownership of 35,084 shares represents a very small fraction (0.016%) of the total shares outstanding, indicating low ownership concentration from this individual.
• Dilution Impact: The filing also reports a grant of 50,814 stock options. The combined total of 70,583 new potential shares (from RSUs and options) represents a potential dilution of approximately 0.032% of shares outstanding, which is minimal and unlikely to concern existing shareholders.
• Transaction Significance: Based on the transaction's value being less than 0.1% of market cap and shares involved being less than 0.1% of outstanding shares, the event is classified as having low significance.

Market Impact Analysis

Stock Impact Prediction

• Direction: Neutral
• Reasoning: Equity awards to directors are a common and expected form of compensation. The market typically does not react to these routine filings as they do not signal new information about the company's performance or outlook.

Volume & Sentiment

• Expected Volume Impact: No significant impact on trading volume is anticipated.
• Sentiment Indicator: Neutral. This is a standard corporate governance action, not a discretionary insider trade.

Investment Insights

Positive Market Indicators

• Equity-based compensation can align the interests of directors with those of shareholders.

Risk Factors

• No immediate risk factors are apparent from this filing.

Key Takeaways

1. Routine Compensation: This Form 4 filing details a standard equity grant to a director, not an open-market purchase or sale.
2. Low Materiality: The size of the grant is negligible compared to the company's market capitalization and total shares outstanding.
3. Minimal Dilution: The combined impact of the stock and option grants results in a very low potential dilution for existing shareholders.

Additional Context

Transaction Notes

• Vesting Schedule: The footnote indicates that both the options and RSUs vest in equal annual installments over three years, which is a typical retention mechanism.
• Dual Grant: The filing includes both a non-derivative (Common Stock/RSU) grant and a derivative (Stock Option) grant, which is common for executive and director compensation packages.